{"nctId":"NCT00425698","briefTitle":"Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation","startDateStruct":{"date":"2007-02"},"conditions":["Kidney Transplantation"],"count":88,"armGroups":[{"label":"intravenous erythropoietin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Recombinant erythropoietin alpha (rHuEPO alpha)","Drug: Placebo"]},{"label":"intravenous placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Recombinant erythropoietin alpha (rHuEPO alpha)","otherNames":["Erypo"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Signed written informed consent\n2. Male or female aged 18 to 70 years without restricted legal competence and being able to follow the trial instructions\n3. Cadaveric renal transplant, cold ischemia time below 24 h, and standard immunosuppressive regimen\n4. A haemoglobin level \\> 8 and \\< 14 g/dl\n5. Treatment with standard immunosuppression (steroids, cyclosporine A, tacrolimus, MMF or azathioprine)\n6. In patient with diabetes mellitus HbA1c \\< 9%\n\nExclusion Criteria:\n\n1. Previous or current myelodysplastic or -proliferative disorders\n2. History of cancer within the last 5 years.\n3. Systemic chemotherapy or radiotherapy\n4. Higher degree renal anemia or persistent Hb \\> 14 g/dl\n5. Treatment with other stem cell growth factors cells like GM-CSF, VEGF\n6. Bleeding episodes within 3 month prior transplantation\n7. Sitting diastolic BP \\> 110 mmHg or sitting systolic BP \\> 170 mmHg\n8. Known intolerance of rHuEpo or analogs\n9. Cardiovascular event within 6 months prior transplantation\n10. Thromboembolic event within 6 months prior transplantation\n11. Relevant stenosis of extra- and intracranial, and peripheral arteries\n12. Systemic diseases (SLE or vasculitis)\n13. Acute or chronic infection and/or CRP \\> 10 mg/l prior transplantation\n14. Hemolysis or disorders of blood formation (e.g., thalassemia)\n15. Further organ transplants or combined organ transplantation\n16. Pregnancy or inadequate contraception\n17. Psychiatric or emotional problems, or chronic seizures\n18. Unwillingness to participate satisfactorily for the entire trial period\n19. Participation in a clinical trial within 30 days prior to study inclusion","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)","description":"Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":"28"},{"groupId":"OG001","value":"46","spread":"22"}]}]}]},{"type":"SECONDARY","title":"Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)","description":"Estimated glomerular filtration rate (eGFR) was assessed using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)equation","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":44},"commonTop":[]}}}